Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Videos

Posted on 12 February 2014 |

Expert views and opinion

International experts discuss hot topics in the modern management of patients with dyslipidaemia.

Topics include:

  • Cholesterol metabolism
  • The role of PCSK9 in lipid metabolism
  • Modern diagnosis and management of familial hypercholesterolaemia around the world
  • Recent trials
  • Key messages from international congresses
PlayHow best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes
How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes
PlayWhat’s in the PCSK9 pipeline?
What’s in the PCSK9 pipeline?
PlayEAS Congress: Lowering lipoprotein(a) for clinical benefit: How much?
EAS Congress: Lowering lipoprotein(a) for clinical benefit: How much?
PlayEAS Consensus Panel: Statins do not impair cognitive function
EAS Consensus Panel: Statins do not impair cognitive function
PlayEAS Congress: FOURIER analysis shows benefit of PCSK9 inhibition in patients with elevated lipoprotein(a)
EAS Congress: FOURIER analysis shows benefit of PCSK9 inhibition in patients with elevated lipoprotein(a)
PlayThe Word from ACC 2018: ODYSSEY Outcomes
The Word from ACC 2018: ODYSSEY Outcomes
PlayHighlights from ACC.2018: Poster presentations
Highlights from ACC.2018: Poster presentations
PlayWill the trial evidence now overcome barriers to the use of PCSK9 inhibition?
Kausik Ray Will the trial evidence now overcome barriers to the use of PCSK9 inhibition?
PlayWill FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?
Steve Nicholls Will FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?
PlayDo FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?
Ulf Landmesser Do FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?
PlayProfessor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?
Steve Nicholls Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?
PlayProfessor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): Would you have expected a greater magnitude of benefit for the primary outcome in ODYSSEY Outcomes?
Steve Nicholls Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): Would you have expected a greater magnitude of benefit for the primary outcome in ODYSSEY Outcomes?
PlayProfessor Raul Santos (University of São Paulo, Brazil): Why was the mortality benefit in ODYSSEY Outcomes only evident after 1 year of follow-up?
Raul Santos Professor Raul Santos (University of São Paulo, Brazil): Why was the mortality benefit in ODYSSEY Outcomes only evident after 1 year of follow-up?
PlayProfessor Raul Santos (University of São Paulo, Brazil): What are the key take home messages from ODYSSEY Outcomes?
Raul Santos Professor Raul Santos (University of São Paulo, Brazil): What are the key take home messages from ODYSSEY Outcomes?
PlayWill ODYSSEY Outcomes change the management of ACS patients?
Raul Santos Will ODYSSEY Outcomes change the management of ACS patients?
PlayWhat is the take home message from ODYSSEY Outcomes regarding the role of LDL cholesterol in CVD prevention?
Lluís Masana What is the take home message from ODYSSEY Outcomes regarding the role of LDL cholesterol in CVD prevention?
PlayHow do you explain the different mortality results in ODYSSEY Outcomes versus FOURIER?
Francois Mach How do you explain the different mortality results in ODYSSEY Outcomes versus FOURIER?
PlayDoes ODYSSEY Outcomes align with FOURIER and the SPIRE cardiovascular outcomes studies?
Steve Nicholls Does ODYSSEY Outcomes align with FOURIER and the SPIRE cardiovascular outcomes studies?
PlayODYSSEY Outcomes and FOURIER in context
ODYSSEY Outcomes and FOURIER in context
PlayInclisiran marches on: ORION-4 cardiovascular outcomes study launches
Inclisiran marches on: ORION-4 cardiovascular outcomes study launches
PlayProf John Chapman discusses safety data from the ODYSSEY Outcomes study
Prof John Chapman discusses safety data from the ODYSSEY Outcomes study
PlayProf Henry Ginsberg discusses the ODYSSEY Outcomes topline data
Prof Henry Ginsberg discusses the ODYSSEY Outcomes topline data
PlayProf Greg Schwartz Clinical implications of ODYSSEY Outcomes
Prof Greg Schwartz Clinical implications of ODYSSEY Outcomes
PlayProf Greg Schwartz Key results of ODYSSEY Outcomes
Prof Greg Schwartz Key results of ODYSSEY Outcomes
PlayProf Greg Schwartz Rationale and design of ODYSSEY Outcomes
Prof Greg Schwartz Rationale and design of ODYSSEY Outcomes
PlayWOSCOPS analysis: Take home messages for clinicians
WOSCOPS analysis: Take home messages for clinicians
PlayImplications from the WOSCOPS analysis
Implications from the WOSCOPS analysis
PlayESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors
Ulf Landmesser ESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors
PlayTreatment with evolocumab avoids the use of lipoprotein apheresis in high risk patients
Frederick J. Raal Treatment with evolocumab avoids the use of lipoprotein apheresis in high risk patients
PlayORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses
Bertrand Cariou ORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses
PlayTAUSSIG: Evolocumab shows benefit in children with homozygous familial hypercholesterolaemia
TAUSSIG: Evolocumab shows benefit in children with homozygous familial hypercholesterolaemia
PlayFOURIER update: new impetus for guideline groups to reconsider LDL targets
John Chapman FOURIER update: new impetus for guideline groups to reconsider LDL targets
PlayWill CANTOS and REVEAL change how we view the clinical use of PCSK9 inhibitors?
Anthony Wierzbicki Will CANTOS and REVEAL change how we view the clinical use of PCSK9 inhibitors?
PlayImplications of very low LDL cholesterol levels
John Chapman Implications of very low LDL cholesterol levels
PlayHow does statin intolerance impact on clinical outcome?
How does statin intolerance impact on clinical outcome?
PlayHow to diagnose statin intolerance?
How to diagnose statin intolerance?
PlayDr Peter Lansberg: What does FOURIER mean for FH patients?
Peter Lansberg Dr Peter Lansberg: What does FOURIER mean for FH patients?
PlayThe Word from ACC 2017 – Implications for Practice
John Chapman The Word from ACC 2017 – Implications for Practice
PlayThe Word from ACC 2017  – Key Results
John Chapman The Word from ACC 2017 – Key Results
PlayAccess to PCSK9 inhibitor treatment: NLA survey provides important pointers
Access to PCSK9 inhibitor treatment: NLA survey provides important pointers
PlayFOURIER in the Hot Seat: What are the Implications for practice and access?
Henry Ginsberg John Chapman FOURIER in the Hot Seat: What are the Implications for practice and access?
PlayDr Brian Ference sets the record straight on questions about benefit in FOURIER
Brian Ference Dr Brian Ference sets the record straight on questions about benefit in FOURIER
PlayEvents are the driver in PCSK9 cardiovascular outcomes trials
Evan Stein Events are the driver in PCSK9 cardiovascular outcomes trials
PlayProf Evan Stein: What are the key messages from FOURIER?
Evan Stein Prof Evan Stein: What are the key messages from FOURIER?
PlayProf Ulf Landmesser: How can we ensure the best value from PCSK9 inhibitor therapy?
Ulf Landmesser Prof Ulf Landmesser: How can we ensure the best value from PCSK9 inhibitor therapy?
PlayProf Steve Nicholls: How can FOURIER improve our clinical practice?
Steve Nicholls Prof Steve Nicholls: How can FOURIER improve our clinical practice?
PlayProf Ulf Landmesser: How will FOURIER impact practice?
Ulf Landmesser Prof Ulf Landmesser: How will FOURIER impact practice?
PlayProf Steve Nicholls: Is there a link between the benefit of evolocumab observed in GLAGOV & FOURIER?
Steve Nicholls Prof Steve Nicholls: Is there a link between the benefit of evolocumab observed in GLAGOV & FOURIER?
PlayProf Steve Nicholls: Is FOURIER a game changer?
Steve Nicholls Prof Steve Nicholls: Is FOURIER a game changer?
PlayProf Robert Rosenson: REGARDS study adds to EBBINGHAUS reassures on lack of effect on neurocognition at low LDL-C
Prof Robert Rosenson: REGARDS study adds to EBBINGHAUS reassures on lack of effect on neurocognition at low LDL-C
PlayProf Raul Santos: How can PCSK9 monoclonal antibody therapy be cost effective?
Raul Santos Prof Raul Santos: How can PCSK9 monoclonal antibody therapy be cost effective?
PlayProf Kausik Ray: How will FOURIER impact FH care?
Kausik Ray Prof Kausik Ray: How will FOURIER impact FH care?
PlayProf Francois Mach: How will FOURIER impact guidelines
Francois Mach Prof Francois Mach: How will FOURIER impact guidelines
PlayProf Francois Mach discusses EBBINGHAUS
Francois Mach Prof Francois Mach discusses EBBINGHAUS
PlayProf Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition
Raul Santos Prof Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition
PlayProf Kausik Ray: Inclisiran, new kid on the block, looks good in ORION
Kausik Ray Prof Kausik Ray: Inclisiran, new kid on the block, looks good in ORION
PlayProf Kausik Ray: Analyses FOURIER, SPIRE-2 and ODYSSEY outcomes
Kausik Ray Prof Kausik Ray: Analyses FOURIER, SPIRE-2 and ODYSSEY outcomes
PlayProf Henry Ginsberg: Data needed on the diabetes subgroup in FOURIER
Henry Ginsberg Prof Henry Ginsberg: Data needed on the diabetes subgroup in FOURIER
PlayProf Raul Santos: SPIRE trials with bococizumab
Raul Santos Prof Raul Santos: SPIRE trials with bococizumab
PlayProf Philip Barter: How do we translate the FOURIER data to clinical practice?
Philip Barter Prof Philip Barter: How do we translate the FOURIER data to clinical practice?
PlayProf John Chapman: FOURIER – Why was there no significant effect on CV mortality?
John Chapman Prof John Chapman: FOURIER – Why was there no significant effect on CV mortality?
PlayProf John Chapman: FOURIER endpoint data
John Chapman Prof John Chapman: FOURIER endpoint data
PlayPCSK9 Forum Editor Professor Philip Barter discusses FOURIER
Philip Barter PCSK9 Forum Editor Professor Philip Barter discusses FOURIER
PlayTake home message on FOURIER
Philip Barter Take home message on FOURIER
PlayPCSK9 Forum Editor Professor Henry Ginsberg discusses FOURIER
Henry Ginsberg PCSK9 Forum Editor Professor Henry Ginsberg discusses FOURIER
PlayCountdown to FOURIER: What are the implications for patients?
Anthony Wierzbicki Countdown to FOURIER: What are the implications for patients?
PlayCould PCSK9 inhibitors be used in FH children?
Philip Barter Could PCSK9 inhibitors be used in FH children?
PlayLooking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
Anthony Wierzbicki Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
PlayLooking back at 2016: What made the news?
John Chapman Looking back at 2016: What made the news?
PlayPCSK9 inhibitors: cardiovascular benefit vs. diabetes risk
PCSK9 inhibitors: cardiovascular benefit vs. diabetes risk
PlayAnthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016
Anthony Wierzbicki Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016
PlayHeart UK statement on homozygous familial hypercholesterolaemia places PCSK9 inhibitors as second‑line treatment
Anthony Wierzbicki Heart UK statement on homozygous familial hypercholesterolaemia places PCSK9 inhibitors as second‑line treatment
PlaySAFEHEART: Consider more than coronary complications in FH
Raul Santos SAFEHEART: Consider more than coronary complications in FH
PlayPCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
Henry Ginsberg PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
PlayODYSSEY ESCAPE: a view from PCSK9 Forum
Peter Lansberg ODYSSEY ESCAPE: a view from PCSK9 Forum
PlayNews: International Atherosclerosis Society consensus statement on severe familial hypercholesterolaemia
Peter Lansberg News: International Atherosclerosis Society consensus statement on severe familial hypercholesterolaemia
PlayIs lipoprotein(a) a cause of clinical familial hypercholesterolaemia?
Frederick J. Raal Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia?
PlayLow LDL-C, PCSK9 and dementia risk?
Frederick J. Raal Peter Lansberg Low LDL-C, PCSK9 and dementia risk?
PlayTAUSSIG: Does adding evolocumab reduce cardiovascular events in homozygous FH?
Frederick J. Raal TAUSSIG: Does adding evolocumab reduce cardiovascular events in homozygous FH?
PlayChanging the message on LDL cholesterol: Lifetime exposure is key
Peter Lansberg Changing the message on LDL cholesterol: Lifetime exposure is key
PlayESC Congress 2015 buzz: Novel LDL lowering treatments
Steve Nicholls ESC Congress 2015 buzz: Novel LDL lowering treatments
PlayHot Topic siRNA and PCSK9
Peter Lansberg Hot Topic siRNA and PCSK9
PlayODYSSEY 78 week HeFH data: Clinical perspectives
Eric Bruckert ODYSSEY 78 week HeFH data: Clinical perspectives
PlayPCSK9 therapeutics – the next story?
Steve Nicholls PCSK9 therapeutics – the next story?
PlayWhat’s next in the PCSK9 field: small interference RNA therapeutics
What’s next in the PCSK9 field: small interference RNA therapeutics
PlayStart treatment early: Maximise benefit
Frederick J. Raal Start treatment early: Maximise benefit
PlayDutch experience – Improving detection and care
Peter Lansberg Dutch experience – Improving detection and care
PlayHow will PCSK9 inhibitors be used in practice?
Steve Nicholls How will PCSK9 inhibitors be used in practice?
PlayNew cholesterol lowering drugs in news
Philip Barter New cholesterol lowering drugs in news
PlayConsider FH in young heart attack patients
Joost Besseling Consider FH in young heart attack patients
PlayMaking premature CHD history
Sam Gidding Making premature CHD history
PlayHow to identify children with FH
Sam Gidding How to identify children with FH
PlaySafety of lowering LDL-C
Albert Wiegman Safety of lowering LDL-C
PlayEAS Consensus Panel on Paediatric FH
Raul Santos EAS Consensus Panel on Paediatric FH
PlayISA 2015: Evolocumab in TAUSSIG homozygous FH cohort
Frederick J. Raal ISA 2015: Evolocumab in TAUSSIG homozygous FH cohort
PlayNew era in cholesterol-lowering? PCSK9 inhibitors soon available?
Henry Ginsberg John Chapman New era in cholesterol-lowering? PCSK9 inhibitors soon available?
PlayISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia
Albert Wiegman Sam Gidding ISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia
PlayFH in Argentina: Why the European Atherosclerosis Society FH Studies Collaboration (EAS-FHSC) is key
Pablo Corral FH in Argentina: Why the European Atherosclerosis Society FH Studies Collaboration (EAS-FHSC) is key
PlayEuropean Atherosclerosis Society Consensus Panel on statin-associated muscle symptoms: Professor Erik Stroes, Academic Medical Center, the Netherlands
Erik Stroes European Atherosclerosis Society Consensus Panel on statin-associated muscle symptoms: Professor Erik Stroes, Academic Medical Center, the Netherlands
PlayPCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor
Henry Ginsberg PCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor
PlayWeighing the cost versus benefit of PCSK9-targeted therapy
Lluís Masana Weighing the cost versus benefit of PCSK9-targeted therapy
PlayHigh cholesterol: an unmet need
Lluís Masana High cholesterol: an unmet need
PlayLooking ahead with PCSK9 Education & Research Forum
Henry Ginsberg Looking ahead with PCSK9 Education & Research Forum
PlayWhat are the patient priorities for PCSK9 inhibitors?
Henry Ginsberg What are the patient priorities for PCSK9 inhibitors?
PlayDoes PCSK9 inhibition impact atherosclerosis?
Steve Nicholls Does PCSK9 inhibition impact atherosclerosis?
PlayLoss of function mutations in PCSK9: the trigger for therapeutic development
Anne Tybjaerg-Hansen Loss of function mutations in PCSK9: the trigger for therapeutic development
PlayDoes PCSK9 have effects beyond the liver and if so, what is the evidence?
Bertrand Cariou Does PCSK9 have effects beyond the liver and if so, what is the evidence?
PlayFamilial hypercholesterolaemia: putting the patient first
Katherine Wilemon Familial hypercholesterolaemia: putting the patient first
PlayOverlap between HoFH and severe FH and implications for evolocumab
Frederick J. Raal Overlap between HoFH and severe FH and implications for evolocumab
PlayImplications from TESLA for FH management
Frederick J. Raal Implications from TESLA for FH management
PlayImplications from TESLA and early TAUSSIG studies with evolocumab
Gerald Watts Implications from TESLA and early TAUSSIG studies with evolocumab
PlayThe role of PCSK9 inhibitors in FH
Dirk Blom The role of PCSK9 inhibitors in FH
PlayWhat are the gaps in knowledge about the PCSK9 inhibitors
Evan Stein What are the gaps in knowledge about the PCSK9 inhibitors
PlayDo the PCSK9 monoclonal antibodies have neurocognitive effects
Frederick J. Raal Do the PCSK9 monoclonal antibodies have neurocognitive effects
PlayWill the PCSK9 monoclonal antibodies replace other lipid lowering treatment used with statins
Frederick J. Raal Will the PCSK9 monoclonal antibodies replace other lipid lowering treatment used with statins
PlayNew ACC/AHA guidelines for cholesterol management: View from the Editors
Henry Ginsberg New ACC/AHA guidelines for cholesterol management: View from the Editors
PlayLDL-C: how low should clinicians aim for?
Henry Ginsberg LDL-C: how low should clinicians aim for?
PlayLowering LDL-C: How low and for how long?
Evan Stein Lowering LDL-C: How low and for how long?
PlayWhy is it critical to target children with FH?
Albert Wiegman Why is it critical to target children with FH?
PlayDiscusses the 10 countries project in FH
Gerald Watts Discusses the 10 countries project in FH
PlayUnmet needs in children with FH
Sam Gidding Unmet needs in children with FH
PlayODYSSEY long term
Jennifer Robinson ODYSSEY long term
PlayODYSSEY FH and patient unmet needs
Raul Santos ODYSSEY FH and patient unmet needs
PlayODYSSEY FHI FHII
Michel Farnier ODYSSEY FHI FHII
PlayODYSSEY trials at ESC Congress Hotline
Alberto Zambon ODYSSEY trials at ESC Congress Hotline
PlayResidual cardiovascular risk – a role for PCSK9 inhibition
Kausik Ray Residual cardiovascular risk – a role for PCSK9 inhibition
PlayFH issues in low to middle income regions
Dirk Blom FH issues in low to middle income regions
PlayImproving the management of the FH patient
Raul Santos Improving the management of the FH patient
PlayThe role of PCSK9 inhibitors in FH
Dirk Blom The role of PCSK9 inhibitors in FH
PlayImplications from TESLA and early TAUSSIG studies with evolocumab
Gerald Watts Implications from TESLA and early TAUSSIG studies with evolocumab
PlayRationale for TESLA and results
Frederick J. Raal Rationale for TESLA and results
PlayTake home messages from ACC2014
Evan Stein Take home messages from ACC2014
PlayDo the PCSK9 inhibitors have pleiotropic effects?
Erik Stroes Do the PCSK9 inhibitors have pleiotropic effects?
PlayWhat are the current unmet needs?
Erik Stroes What are the current unmet needs?
PlayACC/AHA guidelines: Where do the new treatments fit?
Kausik Ray ACC/AHA guidelines: Where do the new treatments fit?
PlayIn your opinion, what are the optimum patient populations for PCSK9 monoclonal antibody therapy?
Evan Stein In your opinion, what are the optimum patient populations for PCSK9 monoclonal antibody therapy?